DE60114002D1 - VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION - Google Patents

VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION

Info

Publication number
DE60114002D1
DE60114002D1 DE60114002T DE60114002T DE60114002D1 DE 60114002 D1 DE60114002 D1 DE 60114002D1 DE 60114002 T DE60114002 T DE 60114002T DE 60114002 T DE60114002 T DE 60114002T DE 60114002 D1 DE60114002 D1 DE 60114002D1
Authority
DE
Germany
Prior art keywords
inhalation
crystalline particles
preparing crystalline
particles
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60114002T
Other languages
English (en)
Other versions
DE60114002T2 (de
Inventor
Robert William Lancaster
Hardev Singh
Andrew Lewis Theophilus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60114002D1 publication Critical patent/DE60114002D1/de
Publication of DE60114002T2 publication Critical patent/DE60114002T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
DE60114002T 2000-06-29 2001-06-29 VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION Expired - Lifetime DE60114002T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0016040.8A GB0016040D0 (en) 2000-06-29 2000-06-29 Novel process for preparing crystalline particles
GB0016040 2000-06-29
PCT/GB2001/002923 WO2002000199A1 (en) 2000-06-29 2001-06-29 Novel process for preparing and harvesting crystalline particles

Publications (2)

Publication Number Publication Date
DE60114002D1 true DE60114002D1 (de) 2005-11-17
DE60114002T2 DE60114002T2 (de) 2006-07-06

Family

ID=9894720

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60114002T Expired - Lifetime DE60114002T2 (de) 2000-06-29 2001-06-29 VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION

Country Status (9)

Country Link
US (1) US20040045805A1 (de)
EP (1) EP1294360B1 (de)
JP (1) JP2004500984A (de)
AT (1) ATE306252T1 (de)
AU (1) AU2001266219A1 (de)
DE (1) DE60114002T2 (de)
ES (1) ES2248348T3 (de)
GB (1) GB0016040D0 (de)
WO (1) WO2002000199A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
SE0302029D0 (sv) * 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
ITMI20032054A1 (it) 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
GB0406069D0 (en) * 2004-03-17 2004-04-21 Thompson James Process
FR2868789B1 (fr) * 2004-04-09 2008-09-26 Inst Francais Du Petrole Procede et dispositif de traitement d'une charge comportant du butadiene
EP1868577A4 (de) 2005-04-15 2009-12-09 Reddys Lab Inc Dr Lacidipin-partikel
EP1944018A1 (de) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Mikronisierte Partikel mit niedrigdosierten Wirkstoffen für Pulverzubereitungen zur Inhalation
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
PL2229148T3 (pl) * 2007-12-13 2014-08-29 Novartis Ag Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
AU2011305567A1 (en) * 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (de) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Nanokristalle von Fluticasonpropionat
EP2705838A1 (de) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium-Zubereitungen
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2014137982A1 (en) * 2013-03-08 2014-09-12 The Board Of Trustees Of The University Of Illinois Ultrasonic method and apparatus for producing particles having a controlled size distribution
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
CN112933649A (zh) * 2021-02-03 2021-06-11 广西民族师范学院 一种用于化学药物的高效分离方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
SE9804003D0 (sv) * 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
EP1173265B1 (de) * 1999-01-29 2005-12-21 Bristol-Myers Squibb Company Vorrichtung und verfahren zur mit ultraschall beaufschlagten strahlkristallisation

Also Published As

Publication number Publication date
DE60114002T2 (de) 2006-07-06
AU2001266219A1 (en) 2002-01-08
EP1294360B1 (de) 2005-10-12
US20040045805A1 (en) 2004-03-11
ES2248348T3 (es) 2006-03-16
ATE306252T1 (de) 2005-10-15
EP1294360A1 (de) 2003-03-26
WO2002000199A1 (en) 2002-01-03
GB0016040D0 (en) 2000-08-23
JP2004500984A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
DE60114002D1 (de) VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION
DE60118558D1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DE60108042D1 (de) Prozesse zur Herstellung von pulverförmigen Schlagzäh-Modifizierern
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
SE9901875D0 (sv) Novel compounds
DE60124482D1 (de) Verfahren zur Herstellung von Xylylendiamin
DE60139122D1 (de) Verfahren zur produktion von natürlichen medizin präparaten
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
IL165988A0 (en) Process for the preparation of fibrinogen
ATE327257T1 (de) Fester, stabiler und konzentrierter biologisch verdaulicher komplex von orthokieselsäure und prozess zur dessen herstellung
DE50015943D1 (de) Verfahren zur Herstellung von Düngemittelpressgranulaten
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE60323793D1 (de) Verfahren zur Herstellung von Fluorhalogenethern
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin
DE59902263D1 (de) Verfahren zur Herstellung feinteiliger Antiperspirantwirkstoff Suspensionen
DE60114668D1 (de) Prozess zur Herstellung des Anti-Migräne Wirkstoffs Eletriptan
DE60043610D1 (de) Verfahren zur herstellung von l-lysin
DE60002254T2 (de) Verfahren zur Herstellung von 4,6-diaminoresorcin
DE60104789D1 (de) Verfahren zur Herstellung von 2,4,5-Trialkylbenzaldehyden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition